January 15, 2026 | Generative AI, Intelligent Commercialization
Learn how a next-generation approach to field training – powered by GenAI and avatar simulations and enabled through Intelligent Commercialization™ – can transform field force effectiveness by delivering scalable, always-on, confidence-building practice for Medical Affairs and Commercial teams.

In this webcast, Inizio examine why traditional, analog models of training are no longer enough in an environment where HCPs have less time, higher expectations, and demand both scientific depth and concise value. You’ll gain an understanding of the evolving “menu” of AI-enabled upskilling options, what truly differentiates those that drive measurable impact, and a practical framework to evaluate and integrate these capabilities into your own field development strategy.
Watch now to learn how Inizio delivers AI-enabled field training through Intelligent Commercialization™ and how this approach can elevate the effectiveness of your Medical and Commercial teams.
This content was provided by Inizio
Latest Content from Inizio
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,…
Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam
Brighton consultancy adds top honour to its award wins
Brighton-based independent healthcare specialist looks to add award to growing list of accolades
Top UK Healthcare Communications Consultancy Moves to Brighton
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation…
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from…
Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards…
